0.85
-0.025(-2.87%)
Currency In USD
| Previous Close | 0.87 |
| Open | 0.88 |
| Day High | 0.88 |
| Day Low | 0.84 |
| 52-Week High | 4.58 |
| 52-Week Low | 0.69 |
| Volume | 120,291 |
| Average Volume | 5.3M |
| Market Cap | 4.35M |
| PE | -0.19 |
| EPS | -4.51 |
| Moving Average 50 Days | 1.02 |
| Moving Average 200 Days | 1.48 |
| Change | -0.03 |
If you invested $1000 in Autonomix Medical, Inc. Common Stock (AMIX) since IPO date, it would be worth $8.33 as of December 07, 2025 at a share price of $0.845. Whereas If you bought $1000 worth of Autonomix Medical, Inc. Common Stock (AMIX) shares 6 months ago, it would be worth $563.33 as of December 07, 2025 at a share price of $0.845.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Autonomix Medical, Inc. (NASDAQ: AMIX) Announces Release of the Next CEO Corner Segment Highlighting Continued Execution and Strategic Growth
GlobeNewswire Inc.
Nov 26, 2025 1:45 PM GMT
THE WOODLANDS, TX, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the next CEO Corner seg
Autonomix Medical, Inc. Announces Pricing of $5.0 Million Private Placement Priced At The Market Under Nasdaq Rules
GlobeNewswire Inc.
Nov 18, 2025 1:30 PM GMT
THE WOODLANDS, TX, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that it has entered int
Autonomix Medical, Inc. Reports Positive Subgroup Results Demonstrating Sustained Improvements in Quality of Life from Post Hoc Analysis of Pancreatic Cancer PoC Study
GlobeNewswire Inc.
Nov 17, 2025 1:00 PM GMT
EORTC QLQ-C30 subgroup results confirm broad and durable quality-of-life improvements across disease stages and metastasis status, complementing previously reported pain reduction and opioid-free outcomes Late-stage patients showed substantial improv